Alpha anomer of 5-aza-2′-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells

被引:13
作者
Hajek, Miroslav [1 ]
Votruba, Ivan [1 ]
Holy, Antonin [1 ]
Kremerova, Marcela [1 ]
Tloust'ova, Eva [1 ]
机构
[1] Inst Organ Chem & Biochem, Gilead Sci Res Ctr, AS CR, Prague 16610 6, Czech Republic
关键词
alpha-5-aza-2 '-deoxycytidine; DNA hypomethylation; hTERT; c-myc;
D O I
10.1016/j.bcp.2007.10.018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
DNA methylation inhibitors are being extensively studied as potential anticancer agents. In the present study, we compared the capability of alpha anomer of 5-aza-2 '-deoxycytidine (alpha-5-azadCyd) to induce down-regulation of hTERT expression in HL-60 cells with other nucleoside analogs that act as DNA methylation inhibitors: beta-5-azadCyd (decitabine), (S)-9-(2,3-dihydroxypropyl)adenine [(S)-DHPA], isobutyl ester of (R,S)-3-(adenin-9-yl)-2-hydroxypropanoic acid [(R,S)-AHPA-ibu] and prospective DNA methylation inhibitors (S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine [(S)-HPMPazaC] and 5-fluoro-zebularine (F-PymRf). Exposure to a-5-azadCyd induced the down-regulation of hTERT expression in low micromolar concentrations (0.05-50 mu M). A more cytotoxic beta anomer caused a transient up-regulation of hTERT and a subsequent reduction in hTERT mRNA levels at concentrations more than 10 times below its GIC(50) value. In this respect, (S)DHPA and (R,S)-AHPA-ibu were less efficient, since a similar effect was achieved at concentrations above their GIC(50). In contrast, F-PymRf treatment resulted in up to a three-fold induction of hTERT expression within a broad range of concentrations. In all cases, the down-regulation of hTERT expression was concentration-dependent. The correlation was found between c-myc overexpression and transiently elevated hTERT expression after treatment with all tested compounds except for alpha-5-azadCyd and (S)-HPMPazaC. Although the primary task of hypomethylating agents in anticancer therapy lies in reactivation of silenced tumour-suppressor genes, the inhibition of hTERT expression might also be a fruitful clinical effect of this approach. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:965 / 972
页数:8
相关论文
共 38 条
[1]   N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis [J].
Boon, K ;
Caron, HN ;
van Asperen, R ;
Valentijn, L ;
Hermus, MC ;
van Sluis, P ;
Roobeek, I ;
Weis, I ;
Voûte, PA ;
Schwab, M ;
Versteeg, R .
EMBO JOURNAL, 2001, 20 (06) :1383-1393
[2]   NUCLEIC-ACID COMPONENTS AND THEIR ANALOGS .191. SIMPLE SYNTHESIS OF 5-FLUORO-2-PYRIMIDINONE AND ITS N-1-SUBSTITUTED DERIVATIVES [J].
CECH, D ;
BEERBAUM, H ;
HOLY, A .
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1977, 42 (09) :2694-2700
[3]  
Dessain SK, 2000, CANCER RES, V60, P537
[4]  
Devereux TR, 1999, CANCER RES, V59, P6087
[5]   Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1 [J].
Eischen, CM ;
Packham, G ;
Nip, J ;
Fee, BE ;
Hiebert, SW ;
Zambetti, GP ;
Cleveland, JL .
ONCOGENE, 2001, 20 (48) :6983-6993
[6]   Efficacy of DNA hypomethylating capacities of 5-aza-2′-deoxycytidine and its alpha anomer [J].
Fojtova, Miloslava ;
Piskala, Alois ;
Votruba, Ivan ;
Otmar, Miroslav ;
Bartova, Eva ;
Kovarik, Ales .
PHARMACOLOGICAL RESEARCH, 2007, 55 (01) :16-22
[7]   c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I [J].
Grandori, C ;
Gomez-Roman, N ;
Felton-Edkins, ZA ;
Ngouenet, C ;
Galloway, DA ;
Eisenman, RN ;
White, RJ .
NATURE CELL BIOLOGY, 2005, 7 (03) :311-U121
[8]   Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres [J].
Guilleret, I ;
Benhattar, J .
EXPERIMENTAL CELL RESEARCH, 2003, 289 (02) :326-334
[9]   NUCLEIC-ACID COMPONENTS AND THEIR ANALOGS .172. ALIPHATIC ANALOGS OF NUCLEOSIDES, NUCLEOTIDES, AND OLIGONUCLEOTIDES [J].
HOLY, A .
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1975, 40 (01) :187-214
[10]   Phosphonomethoxyalkyl analogs of nucleotides [J].
Holy, A .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (31) :2567-2592